TSX closed
Loading markets…

Advertisement

Stocks

Why Avicanna Inc stock is plummeting today

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:AVCN.TO

Get AVCN alerts:

Photos provided by Pexels

Avicanna Inc's stock has taken a sharp downturn, closing down 7.69% in the last trading session.

Avicanna Inc (AVCN.TO) saw a significant drop in its stock price during the last trading session, closing at CA$0.12. This decline raises concerns about the company's market position and investor sentiment amidst ongoing challenges in the biopharmaceutical sector focused on cannabinoid-based products.

Advertisement

KOHO

Earn cash back with a smarter spending account

Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.

Avicanna Inc

AVCN.TO

Full stock page →

AVCN.TO

Avicanna Inc

Source:WealthAwesomeWealthAwesome
$0.05 (-26.47%)
120 day period
$0.11$0.15$0.19Feb 9May 7Jul 31

Market cap

$15.72M

52W high

$0.30

52W low

$0.10

1W change

-7.41%

Beta

0.33

Analyst Price Targets

Based on analyst covering AVCN

📈

Wall Street analysts forecast AVCN stock price to rise 460.0% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$0.70

+460.0% Upside

Current Price

C$0.13

Last close

Compare analyst targets across the TSX & TSXV →

Analyst ratings and price targets are updated periodically. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on AVCN's historical volatility

HistoricalForecast68%95%
C$0.04C$0.09C$0.13C$0.17C$0.21C$0.25TodayMar 25May 29Jul 31Sep 12Oct 26Dec 8

30-Day Vol

70.3%

Annualized

90-Day Vol

65.4%

Annualized

Trend (90d)

-47.6%

Annualized drift

90d Mean

C$0.11

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$0.12C$0.09C$0.15
60 trading daysC$0.11C$0.08C$0.16
90 trading daysC$0.11C$0.07C$0.16

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Investor takeaway: Investors should closely monitor Avicanna's performance and strategic developments, especially given the recent leadership changes and the overall market volatility in the cannabis sector.

Avicanna's Stock Plummets by 7.69%

With a market cap of approximately CA$15.7 million, Avicanna's recent performance reflects investor apprehension in a challenging market.

Bull case

Avicanna has a strong lineup of cannabinoid-based products and is expanding its market presence. If the company can successfully navigate its current challenges, it may see future growth.

Bear case

The recent leadership change and ongoing market pressures could make it tough for Avicanna to stabilize its stock price and regain investor confidence, especially in such a competitive industry.

Recent Performance Analysis

Advertisement

Avicanna Inc's stock price dropped by 7.69% in the last trading session, closing at CA$0.12. This decline highlights the volatility the company faces in a tough market for cannabis stocks. Investors are responding to both internal and external pressures that could affect the company's growth trajectory.

Leadership Changes and Market Sentiment

Nick Hilborn's recent promotion to Chief Financial Officer may indicate a shift in Avicanna's strategy. However, investors are cautious because leadership changes can bring uncertainty, particularly in a sector already facing significant challenges. The market's reaction to this news reflects broader worries about the company's ability to maintain investor confidence and achieve long-term growth.

Looking Ahead: What’s Next for Avicanna?

As Avicanna navigates this turbulent period, its ability to execute its business plan and adapt to market conditions will be crucial. Investors should keep an eye on upcoming announcements and product developments that could influence the stock's recovery. The biopharmaceutical landscape is competitive, and how Avicanna responds to these challenges will determine its future performance in the market.


Advertisement

Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: July 3, 2026
Last Updated: July 3, 2026

Sponsored links

Advertisement